Srinivas Jegannathan v. The Controller of Patents

In the high-stakes world of pharmaceutical innovation, the difference between a granted patent and a rejected one can mean the survival or demise of years of research. When patent examiners wield the word 'obvious' without sufficient justification, they risk burying genuinely novel breakthroughs under the weight of procedural shortcuts. This case is a powerful reminder that the patentability examination must be rigorous, reasoned, and rooted in the claims as originally filed.

Srinivas Jegannathan, an innovator in the pharmaceutical space, filed Patent Application No. 122/CHE/2006 seeking protection for a novel antibiotic formulation combining Ceftazidime, Tazobactum, and Linezolid. This was not a random mix of existing drugs—it was a carefully crafted combination aimed at tackling serious bacterial infections. However, the Controller of Patents rejected the application, effectively shutting the door on the inventor's claim to exclusivity. Jegannathan refused to accept this outcome and escalated the matter to the High Court, challenging the rejection order.

Jegannathan's central argument was straightforward but powerful: the combination of Ceftazidime, Tazobactum, and Linezolid was not obvious from prior art. He contended that the Controller had failed to properly appreciate the inventive step involved in bringing these three active ingredients together in a single formulation. On the other side, the Controller stood by the rejection, presumably arguing that the combination was a predictable extension of existing knowledge in antibiotic therapy. The legal friction centered on whether the rejection order adequately addressed the non-obviousness requirement—one of the most critical pillars of patentability.

The High Court sided with the appellant. It set aside the Controller's rejection order and remanded the matter back for reconsideration. Critically, the court directed that the examination of patentability must be conducted based on the original claims, particularly if the applicant opted to revert to them. The court found that the initial rejection lacked sufficient reasoning regarding non-obviousness, making the order unsustainable. This was not a blanket approval of the patent, but rather a procedural correction ensuring the application received the thorough, claim-based examination it deserved.

For founders, inventors, and IP professionals, this case delivers a clear lesson: a patent rejection must be backed by substantive reasoning, not just conclusory assertions of 'obviousness.' If you are an applicant facing rejection, insist that the examining authority engage with your original claims and explain precisely why your invention lacks an inventive step. Equally, when drafting patent applications, ensure your claims clearly articulate the novelty and non-obviousness of your combination or formulation—because the strength of your patent often depends on how well your claims frame the invention in the first place.